RaySearch Laboratories AB Stock

Equities

RAY B

SE0000135485

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 06:59:33 2024-05-08 am EDT 5-day change 1st Jan Change
127.4 SEK -0.62% Intraday chart for RaySearch Laboratories AB +5.64% +41.09%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2023 1.02B 93.68M Sales 2024 * 1.14B 104M Capitalization 4.37B 400M
Net income 2023 81M 7.42M Net income 2024 * 127M 11.64M EV / Sales 2023 3.21 x
Net Debt 2023 186M 17.02M Net Debt 2024 * 82.48M 7.56M EV / Sales 2024 * 3.92 x
P/E ratio 2023
37.9 x
P/E ratio 2024 *
34.5 x
Employees 388
Yield 2023
0.78%
Yield 2024 *
1.18%
Free-Float 71.84%
More Fundamentals * Assessed data
Dynamic Chart
C-RAD Partners with RaySearch Laboratories to Improve Radiation Therapy MT
RaySearch Laboratories AB and C-RAD Sign Collaboration Agreement CI
Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024 CI
National Institutes for Quantum Science and Technology Selects RaySearch Laboratories AB for Clinical Use at the QST Hospital CI
Transcript : RaySearch Laboratories AB, 2023 Earnings Call, Feb 23, 2024
RaySearch Laboratories AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
RaySearch Laboratories AB Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024 CI
RaySearch Laboratories AB Proposes Ordinary Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024 CI
Pharmacolog Sells Druglog Product Line to RaySearch Laboratories MT
RaySearch Laboratories AB (OM:RAY B) acquired product line Druglog of Pharmacolog AB for SEK 8.5 million. CI
The Royal Marsden Nhs Foundation Trust to Implement Online Adaptiation Therapy Utilizing Artemis from Raysearch CI
The Froedtert & Medical College of Wisconsin Health Network Selects RayStation CI
RaySearch Laboratories AB Releases Raystation 2024A CI
Vejle Hospital Becomes First Center in the World to Use RayStation for an Online Adaptive Treatment with Augmented CBCT CI
Transcript : RaySearch Laboratories AB, Q3 2023 Earnings Call, Nov 17, 2023
More news

Latest transcript on RaySearch Laboratories AB

1 day-0.62%
1 week+5.64%
Current month+5.64%
1 month+4.43%
3 months+43.95%
6 months+45.27%
Current year+41.09%
More quotes
1 week
117.60
Extreme 117.6
129.60
1 month
110.80
Extreme 110.8
129.60
Current year
84.10
Extreme 84.1
129.60
1 year
55.60
Extreme 55.6
129.60
3 years
40.00
Extreme 40
129.60
5 years
40.00
Extreme 40
193.00
10 years
36.90
Extreme 36.9
274.50
More quotes
Managers TitleAgeSince
Founder 55 99-12-31
Director of Finance/CFO 55 23-07-06
Chief Tech/Sci/R&D Officer 51 00-12-31
Members of the board TitleAgeSince
Founder 79 99-12-31
Founder 55 99-12-31
Chairman 86 04-04-30
More insiders
Date Price Change Volume
24-05-08 127.4 -0.62% 18,978
24-05-07 128.2 +4.06% 60,768
24-05-06 123.2 +4.05% 27,934
24-05-03 118.4 -0.34% 21,929
24-05-02 118.8 -1.49% 26,743

Delayed Quote Nasdaq Stockholm, May 08, 2024 at 06:59 am EDT

More quotes
RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
127.4 SEK
Average target price
135 SEK
Spread / Average Target
+5.97%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW